Login to My NLA Account

test

Click Here for LDL Receptor Slide Presentations

 

The Translational Science of the LDL Receptor: an NLA Core Curriculum Intensive Program provides a comprehensive, in-depth indoctrination to advanced lipid science. This masters-level course is designed to address knowledge, competence, and practice gaps in managing residual CVD risk related to high LDL-C and to provide lipid specialists with improved proficiency on the complexities of LDL metabolism, functionality, and targets of therapy. 

 

The educational curriculum serves to (1) disseminate current, advanced science on LDL metabolism, functionality, and its atherogenic activity, (2) provide a forum for experts in clinical lipidology to convey rapidly evolving research on LDL-C to clinicians, and (3) assess current therapeutic options and therapies in development that may modify LDL-C.


The Translational Science of the LDL Receptor Course is offered as a 1.5-day course prior to the start of the NLA 2017 Scientific Sessions.

Course Curriculum

  • The Discovery of the LDL Receptor
  • Biology and Physiology of the LDL Receptor
  • LDL Receptor Genetics
  • Clinical Considerations Related to LDL Receptor Dysfunction
  • Lp(a) and Interactions with LDL Receptors
  • Mutations Impacting LDL Receptor Function
  • Therapeutic Interventions to Improve LDL Receptor Function
  • Challenging Patient Cases

 

Target Audience
This activity is designed to meet the needs of physicians, pharmacists, nurse practitioners, physician assistants and other healthcare professionals experienced in lipidology and lipid management.

 

Location

Philadelphia Marriott Downtown
1201 Market Street
Philadelphia, PA 91907

 

 

At the conclusion of this activity, participants should be able to:

At the conclusion of this master course, participants will be expected to improve their knowledge and competence and be able to:

  • Identify the genetic causes of high LDL-C including the clinical implications of these genetic disorders;
  • Outline the LDL receptors and metabolic pathways and their pleiotropic effects;
  • Describe the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipoprotein metabolism;
  • Describe treatment strategies for patients insufficiently managed through statin therapy;
  • Identify the new evidence that Lp(a) has a potential pro-inflammatory role as a cardiovascular pathogen;
  • Compare and contrast the relative effectiveness of existing treatments to lower LDL and reduce CVD risk, based on the current clinical trial evidence;
  • Evaluate the clinical effects, safety, and efficacy data for current and emerging treatment options for HoFH patients;
  • Recognize the role of current and emerging therapies for the treatment of HoFH patients;
  • Identify emerging therapies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce CVD risk in patient populations with severely elevated LDL-C levels;
  • Identify novel LDL therapies and assess their role in lowering LDL-C and reversing atherosclerosis;
  • Assess the implications of recent clinical trials for the management of patients with elevated LDL-C. 

The National Lipid Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

CE Credit provided by The National Lipid Association
Pharmacists
The National Lipid Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Day 1 Morning Session - Universal Activity Number - 0624-0000-17-022-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 4.25 contact hour(s) (.425 CEUs) of the Accreditation Council for Pharmacy Education.
Day 1 Afternoon Session - Universal Activity Number - 0624-0000-17-023-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education.
Day 2 Morning Session - Universal Activity Number - 0624-0000-17-024-L01-P (Knowledge)
The National Lipid Association designates this continuing education activity for 4.75 contact hour(s) (.475 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 11 contact hours is provided by The National Lipid Association.
The National Lipid Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Day 1 Morning Session- 4.1 credits; Day 1 Afternoon Session- 2.2 credits; Day 2 Morning Session- 4.7 credits.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

Sergio Fazio, MD, PhD, FNLA

Course Co-Chair
Professor of Medicine
Director of Center for Preventive Cardiology
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology

Anne C. Goldberg, MD, FACP, FNLA

Course Co-Chair
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

James A. Underberg, MD, MS, FNLA

Program Director
Treasurer, National Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine
New York, NY
Diplomate, American Board of Clinical Lipidology

Christie M. Ballantyne, MD, FACP, FACC, FNLA

Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Antonio M. Gotto Jr., MD, DPhil, FNLA

Dean Emeritus and Co-Chairman
Board of Overseers
Lewis Thomas University
Professor Weill Cornell Medical College
New York, NY

Paul N. Hopkins, MD, MSPH, FNLA

Professor of Internal Medicine
Cardiovascular Genetics
University of Utah
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology

Peter H. Jones, MD, FACP, FNLA

Associate Professor of Medicine
Co-director, Lipid Metabolism and Atherosclerosis Clinic
Center for Cardiovascular Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Nathan O. Stitziel, MD, PhD

Assistant Professor of Medicine and Genetics 
Director, Center for Cardiovascular Genetics
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine
St. Louis, MO

Marina Cuchel, MD, PhD

Research Associate Professor
Perelman School of Medicine
University of Pennsylvania
Institute for Translational Medicine
Therapeutics Division of Translational Medicine
& Human Genetics
Pennsylvania, PA